Zacks Research Forecasts Exelixis' Q1 Earnings (NASDAQ:EXEL)

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Stock analysts at Zacks Research cut their Q1 2025 earnings estimates for shares of Exelixis in a research note issued to investors on Monday, March 3rd. Zacks Research analyst E. Bagri now anticipates that the biotechnology company will post earnings of $0.35 per share for the quarter, down from their previous estimate of $0.40. The consensus estimate for Exelixis' current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis' Q3 2025 earnings at $0.50 EPS, FY2025 earnings at $1.92 EPS, Q1 2026 earnings at $0.49 EPS, Q2 2026 earnings at $0.58 EPS, Q3 2026 earnings at $0.58 EPS, Q4 2026 earnings at $0.81 EPS and FY2026 earnings at $2.47 EPS.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%.

Other research analysts have also issued research reports about the company. Citigroup upped their price objective on Exelixis from $38.00 to $45.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th. Barclays upped their price target on shares of Exelixis from $25.00 to $29.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 13th. Stifel Nicolaus increased their price target on shares of Exelixis from $30.00 to $36.00 and gave the company a "hold" rating in a report on Wednesday, February 12th. UBS Group boosted their price objective on shares of Exelixis from $30.00 to $34.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. Finally, Stephens reaffirmed an "equal weight" rating and issued a $29.00 target price on shares of Exelixis in a report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $37.24.

Remove Ads

Exelixis Price Performance

NASDAQ EXEL traded up $0.57 on Thursday, hitting $39.15. 3,877,677 shares of the company's stock were exchanged, compared to its average volume of 2,080,966. The firm has a market cap of $10.96 billion, a price-to-earnings ratio of 22.12, a P/E/G ratio of 1.13 and a beta of 0.57. The firm's 50-day moving average price is $34.99 and its two-hundred day moving average price is $32.12. Exelixis has a fifty-two week low of $20.14 and a fifty-two week high of $40.00.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of EXEL. Stephens Inc. AR acquired a new position in Exelixis during the third quarter worth approximately $251,000. Farther Finance Advisors LLC grew its stake in shares of Exelixis by 467.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 3,940 shares of the biotechnology company's stock valued at $102,000 after buying an additional 3,246 shares during the period. Van ECK Associates Corp increased its holdings in shares of Exelixis by 66.2% during the 3rd quarter. Van ECK Associates Corp now owns 173,584 shares of the biotechnology company's stock worth $4,916,000 after buying an additional 69,134 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its position in shares of Exelixis by 263.1% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 483,064 shares of the biotechnology company's stock worth $12,536,000 after buying an additional 350,026 shares during the period. Finally, QRG Capital Management Inc. boosted its holdings in Exelixis by 6.4% in the third quarter. QRG Capital Management Inc. now owns 54,879 shares of the biotechnology company's stock valued at $1,424,000 after acquiring an additional 3,321 shares during the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Exelixis news, EVP Patrick J. Haley sold 52,636 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the transaction, the executive vice president now owns 303,310 shares of the company's stock, valued at $11,216,403.80. This represents a 14.79 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Christopher J. Senner sold 29,314 shares of Exelixis stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.14, for a total value of $1,059,407.96. Following the completion of the sale, the chief financial officer now directly owns 779,607 shares of the company's stock, valued at approximately $28,174,996.98. This represents a 3.62 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock valued at $5,177,234 over the last 90 days. Insiders own 2.85% of the company's stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.